About Editas Medicine
Editas Medicine is a company based in Cambridge (United States) founded in 2013 by George M Church. Editas Medicine has raised $210 million across 5 funding rounds from investors including Fidelity Investments, Juno Therapeutics and Dr. Reddy's Laboratories. The company has 246 employees as of December 31, 2024. Editas Medicine offers products and services including CRISPR Gene Editing Technology and Experimental Medicines Pipeline. Editas Medicine operates in a competitive market with competitors including Insitro, BridgeBio, Alnylam, ATAI and Forge Biologics, among others.
- Headquarter Cambridge, United States
- Employees 246 as on 31 Dec, 2024
- Founders George M Church
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Editas Medicine, Inc.
-
Annual Revenue
$32.31 M (USD)-58.64as on Dec 31, 2024
-
Net Profit
-$237.09 M (USD)-54.74as on Dec 31, 2024
-
EBITDA
-$233.11 M (USD)-42.91as on Dec 31, 2024
-
Total Equity Funding
$210 M (USD)
in 5 rounds
-
Latest Funding Round
$2 M (USD), Post-IPO
Dec 29, 2023
-
Investors
Fidelity Investments
& 17 more
-
Employee Count
246
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Editas Medicine
Editas Medicine is a publicly listed company on the NASDAQ with ticker symbol EDIT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Editas Medicine
Editas Medicine offers a comprehensive portfolio of products and services, including CRISPR Gene Editing Technology and Experimental Medicines Pipeline.
Technology for revising, removing, and replacing DNA to treat serious diseases.
Pipeline of medicines aimed at developing durable therapies for patients.
People of Editas Medicine
Unlock access to complete
Unlock access to complete
Funding Insights of Editas Medicine
Editas Medicine has successfully raised a total of $210M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Editas Medicine
Editas Medicine has secured backing from 18 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Fidelity Investments, Juno Therapeutics and Dr. Reddy's Laboratories.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked |
Investor details for Editas Medicine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Editas Medicine
Investment portfolio details for Editas Medicine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Editas Medicine
Detailed financials for Editas Medicine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Editas Medicine Comparisons
Peer comparison for Editas Medicine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Editas Medicine
Editas Medicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, Alnylam, ATAI and Forge Biologics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
Detailed competitors of Editas Medicine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Editas Medicine
Complete news archive for Editas Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Editas Medicine
Editas Medicine was founded in 2013.
Editas Medicine is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Cynthia Collins is the current CEO of Editas Medicine.
Editas Medicine is a funded company, having raised a total of $210M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Editas Medicine is 246.
Annual revenue of Editas Medicine is $32.31M as on Dec 31, 2024.
Developer of therapeutics for rare genetic diseases. It has developed a novel class of genome editing therapeutics using CRISPRCas genome editing technology. It is utilized for the treatment of rare genetic eye diseases including Leber congenital amaurosis, and usher syndrome. It is also used for the treatment of beta-thalassemia, Duchenne muscular dystrophy, sickle cell anemia, cystic fibrosis, alpha 1-antitrypsin deficiency, and many more.
Editas Medicine's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Editas Medicine offers CRISPR Gene Editing Technology and Experimental Medicines Pipeline.
Yes, Editas Medicine is publicly traded on NASDAQ under the ticker symbol EDIT.
Editas Medicine has 18 investors. Key investors include Fidelity Investments, Juno Therapeutics, Dr. Reddy's Laboratories, Khosla Ventures, and T. Rowe Price.
The ticker symbol of Editas Medicine is EDIT on NASDAQ.